India's religious and political leaders are reassessing prasad practices following controversy over Tirupati temple’s laddus. Karnataka man...

The Akhil Bharatiya Akhara Parishad has suggested distributing mishri, cardamom seeds, and dry fruits as prasad in temples instead of prepa...

The Akhil Bharatiya Akhara Parishad has suggested distributing traditional offerings like sugar crystals, cardamom seeds, and dry fruits as...

Andhra Pradesh Deputy Chief Minister Pawan Kalyan has begun an 11-day 'Prayaschitta Diksha' at Sri Dasavatara Venkateswara Swamy Temple in ...

Andhra Pradesh Deputy Chief Minister Pawan Kalyan has accused the previous government of altering the Tirumala Tirupati Devasthanams board ...

Andhra Pradesh Deputy Chief Minister Pawan Kalyan has begun an 11-day penance at Sri Dasavatara Venkateswara Swamy Temple. He is fasting to...

Union Food Minister Prahlad Joshi has called for a thorough investigation into claims of animal fat in Tirupathi's prasad. The Telugu Desam...

Andhra Pradesh CM Chandrababu Naidu's allegations against former CM Jagan Mohan Reddy over the use of animal fat in Tirupati temple prasad ...

"President's Police Medals for Distinguished Service have been awarded to six officers while Police Medals for Meritorious Service have bee...

The Tirumala Tirupati Devasthanam is mulling raising rates for various services after a dip was noted in its daily revenue post-note ban.

The company management also reiterated its aspiration of USD 5 billion in sales by FY2018 with inorganic growth being a key component, too.

The plan will essentially have details on new segments, expansion strategy into international markets and how to scale up its dairy busines...

Facilities of leading Indian drugmakers including Ranbaxy and Wockhardt were blacklisted by the US regulator last year.

Barclays reiterated its overweight rating on Glenmark Pharmaceuticals after the company's first quarter results exceeded analyst expectatio...

Barclays has retained its 'Overweight' rating on Dr Reddy's Laboratories and kept its target price of Rs 1,991.

Barclays has retained its 'Overweight' rating on Lupin after the US FDA approved capsules for Lupin's flagship generic drug Suprax.

The growth rate for the domestic Indian pharmaceutical market is set to rise over medium-term.